
Innovation, E-Comm and COVID: Summarizing Brightfield Group’s 2020 mid-year US CBD update
COVID-19 Impact In the first half of 2020, CBD companies are experiencing a loss in revenue due to store closures and consumer concerns about Coronavirus
COVID-19 Impact In the first half of 2020, CBD companies are experiencing a loss in revenue due to store closures and consumer concerns about Coronavirus
When Rylie Maedler addresses an audience there’s rarely a dry eye left in the room. By the end of her story, Rylie has gotten under
I am a pharmacist. When I studied pharmaceutical science at Sydney University 24 years ago we were not taught about the Endocannabinoid System (ECS). We
When I was at Pharmacy School at Sydney University, more than 20 years ago, we learned the pharmaceutical and clinical sciences ranging from the design,
What a stressful time this is for all of us. People across the globe have been affected by a new, severe, physical illness making the
Cannabis Investing in a Coronavirus World 60 days ago, cannabis investors were excited about 2020. More states and countries legalized, supply chains were ready,
* Keynote Address: Camm Battley, Chief Corporate Officer, Aurora Cannabis, Inc.
* Africa Landscape
* GMP for Export
* Legal Panel
* Investment Panel: Market Leaders in the African Market
* Welcome
* Traceability
* Genetics
* Tissue Culture
* Grow – outdoor, greenhouse, indoor
* Terpenes
* Roots
OR
* Welcome
* Clinical Trials in Israel
* Clinical Trials: ADD, Autism, and Anxiety and CBD
* Innovative Methodologies in Clinical Trials
* Patient Stories
* Dosage
* Delivery